These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 32381956)
21. Prospects for immunotherapy in cervical cancer. Immunol Today; 1996 Jul; 17(7):299. PubMed ID: 8763810 [No Abstract] [Full Text] [Related]
22. [Individualization of treatment based on biological behavior in uterine cervical cancer]. Teshima K; Yamamoto K; Noda K Gan To Kagaku Ryoho; 1986 Sep; 13(9):2726-33. PubMed ID: 3753021 [TBL] [Abstract][Full Text] [Related]
23. CONSENSUS REPORT ON THE PREVENTION, DIAGNOSIS, AND TREATMENT OF CERVICAL CANCER - A PERSPECTIVE FROM THE IMMUNE SYSTEM TOWARD IMMUNOTHERAPY. Cetina-Pérez L; Castro-Eguiluz D Rev Invest Clin; 2020; 72(4):185-187. PubMed ID: 33064681 [No Abstract] [Full Text] [Related]
24. Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers. Zhang L; Zhou F; Zhao KN Curr Cancer Drug Targets; 2017; 17(6):512-521. PubMed ID: 27993116 [TBL] [Abstract][Full Text] [Related]
25. Gearing up T-cell immunotherapy in cervical cancer. Chauhan SR; Bharadwaj M Curr Probl Cancer; 2018; 42(2):175-188. PubMed ID: 29776594 [TBL] [Abstract][Full Text] [Related]
26. [Targeted therapy in locally and metastatic recurrent cervical cancers]. Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657 [TBL] [Abstract][Full Text] [Related]
27. Global strategies for the treatment of early-stage and advanced cervical cancer. Dueñas-González A; Campbell S Curr Opin Obstet Gynecol; 2016 Feb; 28(1):11-7. PubMed ID: 26626039 [TBL] [Abstract][Full Text] [Related]
29. [Effect of 5'-DFUR used concurrently in radiotherapy and immunotherapy uterine cervical cancer--pilot study. Study of 5'-DFUR for Uterine Cervical Cancer]. Hatae M; Noda K; Yajima A; Sato S; Terashima Y; Ochiai K; Sasaki H; Mizutani K; Honjo H; Yamamoto T; Ozaki M; Yamamoto K; Hasegawa K; Nishimura R; Kudo T; Kobashi Y; Yakushiji M; Sugiyama T; Hasuo Y; Onishi Y Gan To Kagaku Ryoho; 1998 Apr; 25(5):705-11. PubMed ID: 9571968 [TBL] [Abstract][Full Text] [Related]
30. Treg cells in different forms of uterine cancer. Hou F; Ma D; Cui B Clin Chim Acta; 2013 Jan; 415():337-40. PubMed ID: 23178746 [TBL] [Abstract][Full Text] [Related]
31. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response. Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171 [TBL] [Abstract][Full Text] [Related]
33. A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer. Jiang P; Wang L; Hou B; Zhu J; Zhou M; Jiang J; Wang L; Chen S; Zhu S; Chen J; Zhang L Theranostics; 2018; 8(13):3544-3558. PubMed ID: 30026865 [TBL] [Abstract][Full Text] [Related]
34. Major clinical research advances in gynecologic cancer in 2015. Suh DH; Kim M; Kim HJ; Lee KH; Kim JW J Gynecol Oncol; 2016 Nov; 27(6):e53. PubMed ID: 27775259 [TBL] [Abstract][Full Text] [Related]
35. [History of cancer therapy]. Yamabe T Nihon Rinsho; 2004 Oct; 62 Suppl 10():22-7. PubMed ID: 15535200 [No Abstract] [Full Text] [Related]